Patents Assigned to Mission Pharmacal Company
-
Patent number: 11458104Abstract: A solid pharmaceutical composition is provided that includes a core, an inner coating, and an outer coating. The core includes tiopronin as an active agent. Further, the inner coating, which includes a cellulose-based polymer, surrounds the core, and the outer coating, which includes an enteric polymer, surrounds the inner coating. As a result of the specific components of the solid pharmaceutical composition, the solid pharmaceutical composition exhibits a fed state Cmax of tiopronin that is at least 70% of a 12-hour fasted state Cmax of tiopronin after oral administration of the solid pharmaceutical composition when administered as a 300 milligram dose. As such, it is possible for the solid pharmaceutical composition to be administered orally with or without food (e.g., in a fed or fasted state) while still achieving a desired maximum plasma concentration of the tiopronin in a delayed release formulation.Type: GrantFiled: September 5, 2019Date of Patent: October 4, 2022Assignee: MISSION PHARMACAL COMPANYInventors: Jon Taylor, Stuart Smoot, Stuart Schoenherr, Paul Werchan
-
Patent number: 11007151Abstract: A sprayable zinc oxide composition is provided. The sprayable zinc oxide composition can be used in the treatment of various skin conditions. The sprayable zinc oxide composition includes zinc oxide particles and a fluoro-olefin propellant. The present inventors have found that by selecting a propellant having a certain specific gravity, vapor pressure, and molecular weight, and by controlling the viscosity of the various components of the composition, the resulting zinc oxide composition resists settling such that a substantially homogeneous distribution of zinc oxide particles is maintained and can be evenly sprayed onto a surface without running once applied.Type: GrantFiled: February 11, 2015Date of Patent: May 18, 2021Assignee: Mission Pharmacal CompanyInventors: Thomas Dann, Renee Nelson, Brian Wagner, Mary Walter
-
Patent number: 10239685Abstract: A spray delivery system including a sprayable active agent composition housed within a container is provided that can be used in the treatment of various skin conditions. The composition includes a hydrofluoro-based propellant, a carrier fluid, and active agent particles, and has a viscosity ranging from about 500 centipoise to about 10,000 centipoise. The container includes a dip tube; a valve assembly that includes a valve body, a stem comprising a stem orifice, and a vapor tap; and an actuator. The dip tube is coupled to the actuator by the valve assembly, and the actuator is depressed to dispense the emulsion. By selectively controlling the components and viscosity of the composition and the dimensions of the container components, the active agent particles resist settling so a substantially homogeneous distribution of the particles is maintained. Thus, the composition can be evenly dispensed from the container as a fine mist without clogging.Type: GrantFiled: February 11, 2015Date of Patent: March 26, 2019Assignee: Mission Pharmacal CompanyInventors: Thomas Dann, Renee Nelson, Brian Wagner, Mary Walter
-
Patent number: 9700510Abstract: A sprayable emulsion is provided. The emulsion can be used in the treatment of various skin conditions. The emulsion includes a hydrofluoro-based propellant, an emulsification system, an oil phase, a water phase, and active agent particles. Further, the emulsification system includes at least one nonionic emulsifier. The emulsion has a viscosity ranging from about 500 centipoise to about 10,000 centipoise and a hydrophilic to lipophilic balance (HLB) value of from about 2 to about 12. The present inventors have found that by selectively controlling the nature of the emulsification system and the viscosity of the emulsion, the active agent particles resist settling such that a substantially homogeneous distribution of the active agent particles is maintained and can be evenly sprayed onto a surface without running once applied.Type: GrantFiled: June 6, 2016Date of Patent: July 11, 2017Assignee: Mission Pharmacal CompanyInventors: Thomas Dann, Renee Nelson, Brian Wagner, Mary Walter
-
Publication number: 20170182006Abstract: The present disclosure provides novel formulations suitable for the intravaginal delivery of tinidazole, as well as methods of using the same.Type: ApplicationFiled: August 10, 2016Publication date: June 29, 2017Applicants: Mission Pharmacal Company, Universite LavalInventors: Michel G. BERGERON, Jian GAO, Rabeea F. OMAR, Mary Ann WALTER
-
Patent number: 9446024Abstract: The present disclosure provides novel formulations suitable for the intravaginal delivery of tinidazole, as well as methods of using the same.Type: GrantFiled: June 25, 2014Date of Patent: September 20, 2016Assignees: Université Laval, Mission Pharmacal CompanyInventors: Michel G. Bergeron, Jian Gao, Rabeea F. Omar, Mary Ann Walter
-
Patent number: 9381156Abstract: A sprayable emulsion is provided. The emulsion can be used in the treatment of various skin conditions. The emulsion includes a hydrofluoro-based propellant, an emulsification system, an oil phase, a water phase, and active agent particles. Further, the emulsification system includes at least one nonionic emulsifier. The emulsion has a viscosity ranging from about 500 centipoise to about 10,000 centipoise and a hydrophilic to lipophilic balance (HLB) value of from about 2 to about 12. The present inventors have found that by selectively controlling the nature of the emulsification system and the viscosity of the emulsion, the active agent particles resist settling such that a substantially homogeneous distribution of the active agent particles is maintained and can be evenly sprayed onto a surface without running once applied.Type: GrantFiled: February 11, 2015Date of Patent: July 5, 2016Assignee: Mission Pharmacal CompanyInventors: Thomas Dann, Renee Nelson, Brian Wagner, Mary Walter
-
Publication number: 20150080443Abstract: The present disclosure provides novel formulations suitable for the intravaginal delivery of tinidazole, as well as methods of using the same.Type: ApplicationFiled: June 25, 2014Publication date: March 19, 2015Applicants: UNIVERSITE LAVAL, MISSION PHARMACAL COMPANYInventors: Michel G. BERGERON, Jian GAO, Rabeea F. OMAR, Mary Ann WALTER
-
Patent number: 8859824Abstract: Compounds are provided herein which are coordination complexes of the formula, AxByCit2Fz.mH2O, wherein A is a cation selected from certain IA or IIA metal ions in the Periodic Table; B is a cation selected from certain IIA metal ions and certain divalent d-block transition metal ions; A and B are different; “Cit” is tribasic citric acid anion; the stoichiometric ratio of x to y is equal or higher than 1.0 but lower than 8.0; m is 0-12; and z is selected such that electroneutrality is preserved. Compounds provided herein are useful to treat dietary deficiencies, osteoporosis, osteopenia, bone loss, and risk of bone loss, as well as other medical conditions involving the need for administration of the various ions. In addition, the compounds can be used as fluoride sources for dental use and to fluoridate water systems.Type: GrantFiled: January 4, 2010Date of Patent: October 14, 2014Assignee: Mission Pharmacal CompanyInventors: Mary Ann Walter, Jian Gao, Neill Bailey Walsdorf
-
Publication number: 20100184866Abstract: Compounds are provided herein which are coordination complexes of the formula, AxByCit2Fz.mH2O, wherein A is a cation selected from certain IA or IIA metal ions in the Periodic Table; B is a cation selected from certain IIA metal ions and certain divalent d-block transition metal ions; A and B are different; “Cit” is tribasic citric acid anion; the stoichiometric ratio of x to y is equal or higher than 1.0 but lower than 8.0; m is 0-12; and z is selected such that electroneutrality is preserved. Compounds provided herein are useful to treat dietary deficiencies, osteoporosis, osteopenia, bone loss, and risk of bone loss, as well as other medical conditions involving the need for administration of the various ions. In addition, the compounds can be used as fluoride sources for dental use and to fluoridate water systems.Type: ApplicationFiled: January 4, 2010Publication date: July 22, 2010Applicant: Mission Pharmacal CompanyInventors: Mary Ann Walter, Jian Gao, Neill Bailey Walsdorf
-
Patent number: 6887897Abstract: Methods of controlling calcium intake and phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a calcium glutarate compound. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to increase available calcium and contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.Type: GrantFiled: July 31, 2001Date of Patent: May 3, 2005Assignee: Mission Pharmacal CompanyInventors: Neill B. Walsdorf, Sr., George Alexandrides
-
Patent number: 6818228Abstract: A vitamin and mineral supplement containing ULTRADENSE™ calcium citrate and carbonyl iron for use in humans. Calcium in the form of citrate enhances absorption of iron, zinc, and magnesium. ULTRADENSE™ calcium citrate provides more bioavailable calcium than usual preparations of calcium citrate. Carbonyl iron provides iron in a form that significantly reduces the risk to children of accidental iron poisoning from formulations that provide iron in salt form. The supplement may further contain a number of vitamins and minerals in a tablet that is elegantly small, weighing about 1.5-1.6 g. The small size allows ease of swallowing and encourages patient acceptability. Methods of making such a supplement and methods of treating maladies in need of vitamin and mineral supplementation are provided.Type: GrantFiled: June 21, 1996Date of Patent: November 16, 2004Assignee: Mission Pharmacal CompanyInventors: Neill B. Walsdorf, Cindy L. Wabner, George Alexandrides
-
Patent number: 6287607Abstract: A composition useful as a dietary supplement for providing potassium, calcium, and citrate is presented, as well as processes for producing the composition, and methods for using the composition as a dietary supplement. Administration of the composition counters bone loss associated with aging or menopause by providing bioavailable calcium and, simultaneously, delivering alkali load. In addition, administration of the composition produces a substantial increase in urinary citrate, which counters kidney-stone formation.Type: GrantFiled: July 19, 1999Date of Patent: September 11, 2001Assignees: Mission Pharmacal Company, Board of Regents, University of Texas SystemInventors: Charles Y. C. Pak, George Alexandrides, Neill B. Walsdorf
-
Patent number: 5782621Abstract: A vacuum pump useful in penile erection systems is provided. The vacuum pump comprises a piston in a cylinder with intake and exhaust valves. The vacuum producing outstroke is powered by a spring having sufficient force to draw a vacuum no higher than the desired upper safety limit, and the reset stroke is powered manually. The pump is constructed to provide an inherent vacuum limit by selecting a spring which, when fully compressed during a reset stroke, exerts a force against the piston which is less than the force exerted against the piston head by the differential pressure between atmospheric pressure and a preselected maximum vacuum pressure inside the cylinder. Thus, when the maximum vacuum pressure is reached, the piston is not returned for successive pumping.Type: GrantFiled: April 22, 1996Date of Patent: July 21, 1998Assignee: Mission Pharmacal CompanyInventor: Jesse W. Harris
-
Patent number: 5344389Abstract: A combination seal and constricting device and method of use for the external treatment of impotence is provided. The subject device is made of a pliable elastomeric material and is characterized by a centrally disposed cylindrical collar connected at one end thereof to a radially extending skirt having a forwardly facing, annular, elastomeric seating and sealing surface and a rearwardly facing surface substantially flush with one end of said collar. When used in combination with a conventional vacuum erection device, the combination seal and constricting device is positioned at the open end of the evacuation cylinder of the conventional vacuum erection device with the radially extending skirt flush between the open end of the cylinder and the user's groin. In this position, the subject device aids in establishing and maintaining a substantially airtight seal around the open end of the cylinder and the base of the penis during evacuation pumping.Type: GrantFiled: May 28, 1992Date of Patent: September 6, 1994Assignee: Mission Pharmacal Company, Inc.Inventors: Neill B. Walsdorf, Dan K. Crawford, Perry W. Nadig
-
Patent number: 5219889Abstract: A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.Type: GrantFiled: December 3, 1991Date of Patent: June 15, 1993Assignees: The University of Texas System, Mission Pharmacal CompanyInventors: Neill B. Walsdorf, George Alexandrides, Charles Y. C. Pak
-
Patent number: 5075499Abstract: One aspect of the present invention includes the novel compound having the formula:Ca.sub.2 (OOC--CH.sub.2 --COHCOO-CH.sub.2 COO)(CH.sub.3 CHOH-COO)In another aspect of the present invention, a method is provided for the treatment of a calcium related pathology. The inventive method includes the steps of providing a pharmaceutically acceptable composition, including as the active principle the compound dicalcium citrate-lactate, and administering to an individual in need thereof a therapeutically effective amount of said pharmaceutically acceptable composition.In yet another aspect of the present invention, a process is provided for producing the compound dicalcium citrate-lactate.Type: GrantFiled: November 21, 1988Date of Patent: December 24, 1991Assignees: Board of Regents, The University of Texas System, Mission Pharmacal CompanyInventors: Neill B. Walsdorf, George Alexandrides, Charles Y. C. Pak
-
Patent number: 4985593Abstract: A dual mineral salt consisting essentially of magnesium, potassium and citrate. A method for manufacturing the subject salt in a form having a bulk density ranging from about 1.0 g/cc to about 1.3 g/cc is also disclosed, and the use of the subject salt as a dietary supplement are also disclosed.Type: GrantFiled: January 5, 1988Date of Patent: January 15, 1991Assignee: Mission Pharmacal Company, Inc.Inventors: Neill B. Walsdorf, George Alexandrides
-
Patent number: 4921807Abstract: A urine specimen is preserved from bacterial deterioration as to relative constituents by adding thymol. To the thymol-treated specimen, lithium-solution volume-marker is added, then is divided into two (first and second) separate portions. Thereupon, using the first portion, standard conventional measurements and/or analysis is conducted for total volume, pH/acidity, uric acid, citrate, sodium, and potassium. To the second portion, there is added boric acid and hydrochloric acid, followed by standard/conventional measurement and/or analysis for ammonium ion, citrate, calcium, magnesium, phosphorus, oxalate and sulfate. Thereafter the findings are charted and compared to controls.Type: GrantFiled: January 26, 1988Date of Patent: May 1, 1990Assignee: Mission Pharmacal CompanyInventor: Charles Y. C. Pak
-
Patent number: 4904478Abstract: A novel slow-release sodium fluoride preparation and its use. Such slow-release sodium preparation comprises carnauba wax and talc and may be used to provide a safe but effective level of fluoride in serum, optimal for the treatment of osteoporosis. Gastrointestinal side effects are minimized by limiting the amount of fluoride released in the stomach and rheumatic complications are reduced by avoiding toxic levels of fluoride is serum. The amount of fluoride absorbed is nevertheless sufficient to stimulate bone formation and prevent fractures. Thus, the maintenance of serum fluoride as encompassed in this invention, allows for a safe and effective treatment of osteoporosis.Type: GrantFiled: October 22, 1987Date of Patent: February 27, 1990Assignees: Mission Pharmacal Company, Board of Regents, The University of Texas SystemInventors: Neill B. Walsdorf, Charles Y. C. Pak